WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1998003533) ANTISENSE OLIGONUCLEOTIDES AS ANTIBACTERIAL AGENTS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1998/003533    International Application No.:    PCT/US1997/012961
Publication Date: 29.01.1998 International Filing Date: 23.07.1997
Chapter 2 Demand Filed:    23.02.1998    
IPC:
A61K 38/00 (2006.01), C12N 15/11 (2006.01)
Applicants: OLIGOS ETC. AND OLIGOS THERAPEUTICS, INC. [US/US]; 29970 S.W. Town Center Loop W., Wilsonville, OR 97070 (US)
Inventors: ARROW, Amy; (US).
DALE, Roderic, M., K.; (US).
THOMPSON, Theresa, L.; (US)
Agent: FRIEBEL, Thomas, E.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US)
Priority Data:
08/685,575 24.07.1996 US
Title (EN) ANTISENSE OLIGONUCLEOTIDES AS ANTIBACTERIAL AGENTS
(FR) OLIGONUCLEOTIDES ANTI-SENS UTILISES COMME AGENTS ANTIBACTERIENS
Abstract: front page image
(EN)A novel method is provided that teaches the therapeutic use of nuclease resistant oligonucleotides for treating animals having an infection caused by a pathogenic bacterium. The method involves the integration of (1) methods for selecting the correct oligonucleotide, (2) synthesis and purification of nuclease resistant oligonucleotides, and (3) methods for $i(in vitro) analysis of potential antimicrobial oligonucleotides. The described oligonucleotides may comprise modified backbones, sugar residues, bases, or mixtures and have been subject to purification resulting in oligonucleotides that are capable of inhibiting the growth of a broad spectrum of clinically relevant bacterial species.
(FR)Cette invention se rapporte à un nouveau procédé qui démontre l'utilisation thérapeutique d'oligonucléotides résistants aux nucléases pour traiter les animaux souffrant d'une infection causée par une bactérie pathogène. Ce procédé consiste à intégrer: (1) des procédés de sélection de l'oligonucléotide correct; (2) la synthèse et la purification d'oligonucléotides résistants aux nucléases, et (3) des procédés d'analyse $i(in vitro) d'oligonucléotides antimicrobiens potentiels. Les oligonucléotides décrits peuvent comporter des squelettes, des restes de sucres, des bases ou des mélanges modifiés et ont été soumis à une purification, ce qui produit des oligonucléotides capables d'inhiber la croissance d'un large spectre d'espèces bactériennes cliniquement pertinentes.
Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU.
African Regional Intellectual Property Organization (GH, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)